Ocuphire Pharma Statistics
Share Statistics
Ocuphire Pharma has 26.20M shares outstanding. The number of shares has increased by 15.73% in one year.
| Shares Outstanding | 26.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.52M |
| Failed to Deliver (FTD) Shares | 950 |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 930.64K, so 3.55% of the outstanding shares have been sold short.
| Short Interest | 930.64K |
| Short % of Shares Out | 3.55% |
| Short % of Float | 3.93% |
| Short Ratio (days to cover) | 10.1 |
Valuation Ratios
The PE ratio is -6.51 and the forward PE ratio is 9.14.
| PE Ratio | -6.51 |
| Forward PE | 9.14 |
| PS Ratio | 3.41 |
| Forward PS | 0.7 |
| PB Ratio | 1.3 |
| P/FCF Ratio | -58.44 |
| PEG Ratio | n/a |
Enterprise Valuation
Ocuphire Pharma Inc. has an Enterprise Value (EV) of 14.48M.
| EV / Earnings | -1.45 |
| EV / Sales | 0.76 |
| EV / EBITDA | -1.37 |
| EV / EBIT | -1.37 |
| EV / FCF | -13.03 |
Financial Position
The company has a current ratio of 13.35, with a Debt / Equity ratio of 0.
| Current Ratio | 13.35 |
| Quick Ratio | 13.35 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -21.19%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -21.19% |
| Revenue Per Employee | 1.36M |
| Profits Per Employee | -713.29K |
| Employee Count | 14 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 12.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -57.61% in the last 52 weeks. The beta is 0.31, so Ocuphire Pharma 's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | -57.61% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 37.64 |
| Average Volume (20 Days) | 136.35K |
Income Statement
In the last 12 months, Ocuphire Pharma had revenue of $19.05M and earned -$9.99M in profits. Earnings per share was $-0.46.
| Revenue | 19.05M |
| Gross Profit | 19.04M |
| Operating Income | -10.56M |
| Net Income | -9.99M |
| EBITDA | -10.56M |
| EBIT | -10.56M |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
The company has $50.50M in cash and $0 in debt, giving a net cash position of $50.50M.
| Cash & Cash Equivalents | 50.50M |
| Total Debt | 0 |
| Net Cash | 50.50M |
| Retained Earnings | -81.47M |
| Total Assets | 44.83M |
| Working Capital | 40.64M |
Cash Flow
In the last 12 months, operating cash flow was -$1.11M and capital expenditures $0, giving a free cash flow of -$1.11M.
| Operating Cash Flow | -1.11M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.11M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 99.97%, with operating and profit margins of -55.45% and -52.42%.
| Gross Margin | 99.97% |
| Operating Margin | -55.45% |
| Pretax Margin | -52.36% |
| Profit Margin | -52.42% |
| EBITDA Margin | -55.42% |
| EBIT Margin | -55.45% |
| FCF Margin | -5.84% |
Dividends & Yields
OCUP pays an annual dividend of $undefined, which amounts to a dividend yield of undefined%.
| Dividend Per Share | $undefined |
| Dividend Yield | undefined% |
| Dividend Growth (YoY) | undefined% |
| Payout Ratio | undefined% |
| Earnings Yield | undefined% |
| FCF Yield | undefined% |
Analyst Forecast
Currently there are no analyst rating for OCUP.
| Price Target | $undefined |
| Price Target Difference | undefined% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | undefined |
| Piotroski F-Score | undefined |